Clinical Trial Update: Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China [Phase 2]

View source ↗

Summary

BeiGene's Phase 2 trial of BGB-290 in metastatic HER2-negative breast cancer with BRCA mutation in China has completed and posted efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BGB-290

Snippet

Sponsor: BeiGene | Conditions: HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-07